Immunovant insider exercises options, sells 1,500
Rhea-AI Filing Summary
Immunovant, Inc. (IMVT) director Atul Pande exercised fully vested stock options to acquire 1,500 shares of common stock at an exercise price of $8.43 per share and on the same date sold 1,500 shares at $43.27 per share. Following the option exercise, he holds 65,181 options directly, and a separate indirect holding shows 20,000 shares held by a trust. The reported transactions were effected pursuant to a Rule 10b5-1 Plan adopted on December 26, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,500 shares ($52K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Pande Atul
Role
Director
Sold
1,500 shs ($65K)
Approx. gross sale proceeds
$65K
Approx. exercise cost
$13K
Approx. pre-tax spread
$52K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F1, F2 | 1,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,500 | $8.43 | $13K |
| Sale | Common Stock F1 | 1,500 | $43.27 | $65K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 65,181 shares (Direct);
Common Stock — 116,731 shares (Direct);
Common Stock — 20,000 shares (Indirect, By Trust)
Footnotes (2)
- F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
- F2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Key Figures
Options Exercised: 1,500 shares
Exercise Price: $8.43 per share
Shares Sold: 1,500 shares
+5 more
8 metrics
Options Exercised
1,500 shares
Stock options to buy Immunovant, Inc. common stock exercised on August 28, 2026
Exercise Price
$8.43 per share
Exercise price of stock options exercised for 1,500 shares
Shares Sold
1,500 shares
Common stock sold on August 28, 2026 in an open market or private transaction
Sale Price
$43.27 per share
Price per share received for the 1,500 Immunovant, Inc. shares sold
Options Held After Transaction
65,181 options
Total stock options directly held following the reported option exercise
Indirect Shares Held by Trust
20,000 shares
Common stock held indirectly by trust for the reporting person
Option Expiration Date
November 19, 2029
Expiration date of the exercised stock option award
Rule 10b5-1 Plan Adoption Date
December 26, 2025
Date the reporting person adopted the trading plan governing these transactions
Key Terms
Rule 10b5-1 Plan, Stock Option (right to buy), Exercise or conversion of derivative security, indirect, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted..."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) with an exercise price..."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
indirect financial
"ownership_type: indirect, nature_of_ownership: By Trust"
By Trust financial
"nature_of_ownership: By Trust for 20,000 indirect shares"
FAQ
What did Atul Pande report in this Form 4 for IMVT?
He reported exercising 1,500 stock options for Immunovant, Inc. common stock at an exercise price of $8.43 per share and selling 1,500 shares at $43.27 per share on August 28, 2026, under a Rule 10b5-1 Plan.
What is the exercise price of the options exercised in IMVT?
The exercised stock options had an exercise price of $8.43 per share, covering 1,500 shares of Immunovant, Inc. common stock, with the options fully vested and expiring on November 19, 2029.
How many IMVT options does Atul Pande hold after these transactions?
After the reported option exercise, Atul Pande holds 65,181 stock options directly in Immunovant, Inc., according to the post-transaction derivative holdings reported.
Were the IMVT transactions made under a Rule 10b5-1 trading plan?
Yes. A footnote states the reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by Atul Pande on December 26, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
